Skip to main content

Advertisement

SpringerLink
Log in

Long-term outcomes in juvenile dermatomyositis: How did we get here and where are we going?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Juvenile dermatomyositis (JDM) affects two to four children per million. Prior to treatment with corticosteroids, JDM had a high mortality rate (>30%) and left 50% of those who survived with serious permanent impairments. After the introduction of corticosteroids, mortality rapidly dropped to less than 10%, and is currently reported to be less than 2% to 3%. Because most children now survive this illness, there is greater interest in long term outcomes. However, review of the literature shows while much is known about mortality, relatively little is known about long term out-comes such as physical function, quality of life, pain, educa-tional and vocational achievement, patient satisfaction, and ongoing disease activity. Furthermore, the literature that has been published has not typically used the same outcomes making comparisons across studies difficult. Current efforts to identify key outcomes and validate measures for those outcomes will allow researchers in the future to provide this much needed information.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Mendez EP, Lipton R, Ramsey-Goldman R, et al.: US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003, 49:300–305.

    Article  PubMed  Google Scholar 

  2. Symmons D, Sills J, Davis S: The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995, 34:732–736.

    Article  PubMed  CAS  Google Scholar 

  3. Selander P: Dermatomyositis in early childhood. Acta Med Scand 1950, 246:187–203.

    CAS  Google Scholar 

  4. Wedgwood RJP, Cook CD, Cohen J: Dermatomyositis: report of 26 cases in children with a discussion of endocrine therapy in 13. Pediatrics 1953, 12:447–465.

    PubMed  CAS  Google Scholar 

  5. Roberts HM, Brunsting LA: Dermatomyositis in vhildhood: A summary of 40 Cases. Postgrad Med 1954, 16:396–404.

    PubMed  CAS  Google Scholar 

  6. Everett MA, Curtis AC: Dermatomyositis. Arch Intern Med 1957, 100:70–76.

    CAS  Google Scholar 

  7. Bitnum S, Daeschner JrC, Travis LB, et al.: Dermatomyositis. J Pediatr 1964, 64:101–131. Although this is an old reference, this report summarizes the experience in JDM prior to the advent of effective treatments, and remains a valuable resource.

    Article  PubMed  CAS  Google Scholar 

  8. Rose AL: Childhood polymyositis: a follow-up study with special reference to treatment with corticosteroids. Am J Dis Child 1974, 127:518–522.

    PubMed  CAS  Google Scholar 

  9. Goel K, Shanks R: Dermatomyositis in childhood: review of 8 cases. Arch Dis Child 1976, 51:501–506.

    PubMed  CAS  Google Scholar 

  10. Hanson V: Dermatomyositis, scleroderma and polyarteritis nodosa. Clin Rheum Dis 1976, 2:445–467.

    Google Scholar 

  11. Sullivan DB, Cassidy JT, Petty RE, Burt A: Prognosis in childhood dermatomyositis. J Pediatr 1972, 80:555–563.

    Article  PubMed  CAS  Google Scholar 

  12. Sullivan DB, Cassidy JT, Petty RE: Dermatomyositis in the pediatric patient. Arthritis Rheum 1977, 20:327–331.

    PubMed  CAS  Google Scholar 

  13. Pachman LM, Cooke N: Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr 1980, 96:226–234.

    Article  PubMed  CAS  Google Scholar 

  14. Spencer CH, Hanson V, Singsen BH, et al.: Course of treated juvenile dermatomyositis. J Pediatr 1984, 105:399–408.

    Article  PubMed  CAS  Google Scholar 

  15. Taieb A, Guichard C, Salamon R, Maleville J: Prognosis in juvenile dermatopolymyositis: a cooperative retrospective study of 70 cases. Pediatr Dermatol 1985, 2:275–281.

    PubMed  CAS  Google Scholar 

  16. Miller LC, Michael AF, Kim Y: Childhood dermatomyositis: clini-cal course and long-term follow-up. Clin Pediatr 1987, 26:561.

    CAS  Google Scholar 

  17. Miller G, Heckmatt J, Dubowitz V: Drug treatment of dermatomyositis. Arch Dis Child 1983, 58:445–450.

    PubMed  CAS  Google Scholar 

  18. Dubowitz V: Treatment of dermatomyositis in childhood. Arch Dis Child 1976, 51:494–500.

    PubMed  CAS  Google Scholar 

  19. Miller JJ, Koehler J: Persistance of activity in dermatomyositis of childhood. Arthritis Rheum 1977, 20:332–337.

    PubMed  Google Scholar 

  20. Miller JJ: Late progression in dermatomyositis in childhood. J Pediatr 1973, 83:543–548.

    Article  PubMed  Google Scholar 

  21. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT: Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983, 103:882–888. Also an older reference, this paper documents the importance of early and adequate intervention with corticosteroids in JDM to prevent long term sequelae, in particular calcinosis.

    Article  PubMed  CAS  Google Scholar 

  22. Chalmers A, Sayson R, Walters K: Juvenile dermatomyositis: medical, social and economic status in adulthood. CMAJ 1982, 126:31–33.

    CAS  Google Scholar 

  23. Ng Y-T, Ouvrier RA, Wu T: Drug therapy in juvenile dermatomyositis. J Child Neurol 1998, 13:109–112.

    Article  PubMed  CAS  Google Scholar 

  24. Collison CH, Sinal SH, Jorizzo JL, et al.: Juvenile dermatomyositis and polymyositis: a follow-up study of long term sequelae. South Med J 1998, 91:17–22.

    PubMed  CAS  Google Scholar 

  25. Shehata R, Al-Mayouf SM, Al-Dalaan A, et al.: Juvenile dermatomyositis: Clinical profile and disease course in 25 patients. Clin Exp Rheumatol 1999, 17:115–118.

    PubMed  CAS  Google Scholar 

  26. Peloro TM, Miller FI, Hahn TF, Newman ED: Juvenile dermato-myositis: a retrospective review of a 30 year experience. J Am Acad Dermatol 2001, 45:28–34.

    Article  PubMed  CAS  Google Scholar 

  27. Fisler RE, Liang MG, Fuhlbrigge RC, et al.: Aggressive manage-ment of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002, 47:505–511.

    Article  PubMed  Google Scholar 

  28. Pachman LM: Juvenile dermatomyositis: pathophysiology and disease expression. Pediatr Clin North Am 1995, 42:1071–1098.

    PubMed  CAS  Google Scholar 

  29. Huber AM, Lang B, LeBlanc CM, et al.: Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2001, 43:541–549. This paper remains the most wide-ranging outcomes assessment in children with JDM. Its strengths include the use of an inception cohort, the combining of data from four tertiary care pediatric hospi-tals, and the variety of outcomes assessed.

    Article  Google Scholar 

  30. Miller FM, Rider LG, Chung Y, et al.: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatol-ogy 2001, 40:1262–1273. This report is the first attempt to develop a consensus for which out-comes should be assessed in clinical trials in JDM. This is mandatory reading for anyone conducting research in JDM.

    Article  CAS  Google Scholar 

  31. Ruperto N, Ravelli A, Murray K, et al.: Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003, 42:1452–1459. This report is the result of efforts parallel to those of the previous reference to develop consensus on which outcomes should be assessed in JDM. The similarity in the two consensus statements is of considerable interest.

    Article  PubMed  Google Scholar 

  32. Huber AM, Hicks JE, Lachenbruch PA, et al.: Validation of the childhood health assessment questionnaire in the juvenile idiopathic inflammatory myopathies. J Rheumatol 2001, 28:1106–1111.

    PubMed  CAS  Google Scholar 

  33. Feldman BM, Ayling-Campos A, Luy L, et al.: Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995, 22:326–331.

    PubMed  CAS  Google Scholar 

  34. Huber AM, Feldman BM, Rennebohm RM, et al.: Val i dati on and clinical significance of the childhood myositis assess-ment scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004, 50:1595–1603.

    Article  PubMed  Google Scholar 

  35. Rennebohm RM, Jones K, Huber AM, et al.: Normal scores for nine maneuvers of the childhood myositis assessment scale (CMAS). Arthritis Rheum 2004, 51:365–370.

    Article  PubMed  Google Scholar 

  36. Lovell DJ, Lindsley CB, Rennebohm RM, et al.: Development of disease activity and damage indices for the juvenile idio-pathic inflammatory myopathies. II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evalua-tion of muscle function. Arthritis Rheum 1999, 42:2213–2219.

    Article  PubMed  CAS  Google Scholar 

  37. Rider LG, Feldman BM, Perez MD, et al.: Development of vali-dated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, Parent and patient global assessments. Arthritis Rheum 1997, 40:1976–1983.

    Article  PubMed  CAS  Google Scholar 

  38. Bode RK, Klein-Gitelman MS, Miller ML, et al.: Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Care Res 2003, 49:7–15.

    Article  Google Scholar 

  39. Ramanan A, Campbell-Webster N, Tran D, et al.: Initial treat-ment of juvenile dermatomyositis using methotrexate (MTX) and aggressively tapered prednisone (PRED) [abstract]. Pediatr Rheumatol Online Journal 2003, 1:123.

    Google Scholar 

  40. Ramanan A, Feldman BM: Clinical features and outcomes of dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002, 28:833–857.

    Article  PubMed  CAS  Google Scholar 

  41. Lang B, Laxer RM, Murphy G, et al.: Treatment of dermato-myositis with intravenous gammaglobulin. Am J Med 1991, 91:169–172.

    Article  PubMed  CAS  Google Scholar 

  42. Zeller V, Cohen P, Prieur A, Guillevin L: Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and long term followup of 6 cases. J Rheumatol 1996, 23:1424–1427.

    PubMed  CAS  Google Scholar 

  43. Levine T: Rituximab in the treatment of dermatomyositis: an open-label study. Arthritis Rheum 2005, 52:601–607.

    Article  PubMed  CAS  Google Scholar 

  44. Tse S, Lubelsky S, Gordon M, et al.: The arthritis of inflam-matory childhood myositis syndromes. J Rheumatol 2001, 28:192–197.

    PubMed  CAS  Google Scholar 

  45. Huemer C, Kitson H, Malleson P, et al.: Lipodystrophy in patients with juvenile dermatomyositis-evaluation of clinical and meta-bolic abnormalities. J Rheumatol 2001, 28:610–615.

    PubMed  CAS  Google Scholar 

  46. Hicks JE, Drinkard B, Summers RM, Rider LG: Decreased aerobic capacity in children with juvenile dermatomyostis. Arthritis Rheum 2002, 47:118–123.

    Article  PubMed  Google Scholar 

  47. Takken T, Spermon N, Pj H, et al.: Aerobic exercise capacity in patients with juvenile dermatomyositis. J Rheumatol 2003, 30:1075–1080.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Rheumatology, IWK Health Centre, 5850 University Avenue, B3K 6R8, Halifax, Nova Scotia, Canada

    Adam Huber MD

Authors
  1. Adam Huber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian M. Feldman MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huber, A., Feldman, B.M. Long-term outcomes in juvenile dermatomyositis: How did we get here and where are we going?. Curr Rheumatol Rep 7, 441–446 (2005). https://doi.org/10.1007/s11926-005-0048-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-005-0048-1

Keywords

Search

Navigation